We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

21 hedge funds and large institutions have $3.58M invested in Palvella Therapeutics in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 7

28.03% more ownership

Funds ownership: 0.48% → 28.51% (+28%)

49% less funds holding

Funds holding: 41 → 21 (-20)

51% less capital invested

Capital invested by funds: $7.24M → $3.58M (-$3.67M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 19

Holders
21
Holders Change
-20
Holders Change %
-48.78%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
12
Reduced
7
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HVIA
Hudson Valley Investment Advisors
New York
+$156K
2
UBS Group
UBS Group
Switzerland
+$12.1K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$10.9K
4
US Bancorp
US Bancorp
Minnesota
+$327
5
BlackRock
BlackRock
New York
+$56

Top Sellers

Rank Fund Capital Flow
1
LCM
Lynx1 Capital Management
Puerto Rico
-$747K
2
Goldman Sachs
Goldman Sachs
New York
-$332K
3
Citadel Advisors
Citadel Advisors
Florida
-$177K
4
CM
CM Management
Florida
-$105K
5
Renaissance Technologies
Renaissance Technologies
New York
-$72.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
– -$38.8K -2,647 Closed
Squarepoint
27
Squarepoint
New York
– -$26.7K -1,823 Closed
STA
28
Summit Trail Advisors
New York
– -$25.6K -1,750 Closed
TSS
29
Two Sigma Securities
New York
– -$10.7K -728 Closed
Two Sigma Advisers
30
Two Sigma Advisers
New York
– -$6.21K -424 Closed
NSEDCP
31
NJ State Employees Deferred Compensation Plan
New Jersey
– -$5.5K -375 Closed
RJA
32
Raymond James & Associates
Florida
– -$5.5K -375 Closed
Goldman Sachs
33
Goldman Sachs
New York
– -$332K -283 Closed
XT
34
XTX Topco
Cayman Islands
– -$3.8K -259 Closed
CB
35
Commerce Bank
Missouri
– -$3.66K -250 Closed
KAS
36
Kestra Advisory Services
Texas
– -$3.21K -219 Closed
BRWA
37
B. Riley Wealth Advisors
Florida
– -$5.07K -213 Closed
Cerity Partners
38
Cerity Partners
New York
– -$1.89K -129 Closed
TC
39
Truvestments Capital
Florida
– -$205 -14 Closed
Royal Bank of Canada
40
Royal Bank of Canada
Ontario, Canada
– +$11 +1 +33%
1
2

PVLA Hedge Fund Activity: Q2 2024 in Review

21 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2024, worth a combined $3.58M — down 51% from $7.24M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of PVLA and 0 opened new positions — a net loss of 19 holders — while 7 trimmed existing stakes and 12 added.

The largest buyer was Hudson Valley Investment Advisors, adding an estimated $156K. The largest seller was Lynx1 Capital Management, cutting an estimated $747K.

  • 21 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2024, down from 41 in Q1 2024.
  • Funds reported $3.58M of Palvella Therapeutics stock for Q2 2024, down 51% quarter-over-quarter.
  • 0 funds opened new Palvella Therapeutics positions in Q2 2024 and 19 closed out, a net change of -19 holders.
  • The largest Palvella Therapeutics buyer in Q2 2024 was Hudson Valley Investment Advisors, an estimated $156K added.
  • The largest Palvella Therapeutics seller in Q2 2024 was Lynx1 Capital Management, an estimated $747K sold.

Based on aggregated 13F filings for Q2 2024.